Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells
Chien‐Hsing Chang(Immunomedics (United States)), David M. Goldenberg(Unknown), Yang Wang(Kunming University of Science and Technology), Rongxiu Li(Shanghai Jiao Tong University), Donglin Liu(Boston University), Diane L. Rossi(Immunomedics (United States)), Edmund A. Rossi(Immunomedics (United States)), Thomas M. Cardillo(Immunomedics (United States))
Cited by 83
Related Papers
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
|Oncotarget|2015|464
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2017|407